Method for diagnosing preeclampsia by detecting hCRH mRNA
Methods and kits are provided for diagnosing, monitoring, or predicting the conditions of pre-eclaimpsia, fetal chromosomal aneuploidy, and pre-term labor in a pregnant woman, as well as for detecting pregnancy in a woman, by quantitatively measuring in the maternal blood the amount of one or more mRNA species encoding human chorionic gonadotropin β subunit (hCG-β), human placental lactogen (hPL), human corticotropin releasing hormone (hCRH), KiSS-1 metastasis-suppressor (KISS1), tissue factor pathway inhibitor 2 (TPFI2), placenta-specific 1 (PLAC1), or glyceraldehyde-3-phosphate dehydrogenase (GAPDH), and comparing the amount of the mRNA species with a standard control.
1. A method for diagnosing, or predicting preeclampsia in a pregnant woman, the method comprising the steps of:
(i) quantitatively determining the amount of mRNA encoding human corticotropin releasing hormone (hCRH) in the pregnant woman's plasma or serum; and
(ii) comparing the amount of mRNA from step (i) to a standard control representing the amount of hCRH mRNA in the plasma or serum of an average non-preeclamptic pregnant woman, wherein an increase in the amount of mRNA compared with the standard control indicates preeclampsia or an increased risk of developing preeclampsia.
2. The method of claim 1 , wherein step (i) is performed by reverse transcriptase polymerase chain reaction (RT-PCR).
3. The method of claim 1 , wherein step (i) is performed by a polynucleotide hybridization method.
4. The method of claim 1 , wherein the woman is during the first trimester of gestation.
5. The method of claim 1 , wherein the woman is during the second or third trimester of gestation.
6. The method of claim 1 , wherein the pregnant woman's plasma is used in step (i).
7. The method of claim 1 , wherein the pregnant woman's serum is used in step (i).
8. The method of claim 1 , wherein the increase in the amount of mRNA from the standard control is more than 2-fold.